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To the Editor:
We were interested to read the 
article by Evison et al.1 published in the 
January 2015 issue of Journal of Thoracic 
Oncology. We appreciated the idea of 
proposing a risk stratification model for 
negative lymph nodes by endobronchial 
ultrasound guided transbronchial needle 
aspiration (EBUS-TBNA) in lung cancer 
patients. The proposed model increased 
the negative predictive value of EBUS-
TBNA from 91%2 to approximately 
99%. We believe that this model can help 
to discriminate patients that may directly 
proceed to curative treatment after a neg-
ative EBUS-TBNA. On the basis of this 
model, an EBUS-TBNA negative lymph 
node needs no further evaluation if the 
lymph node maximum standardized 
uptake value (SUVmax) is lower than 4, 
the SUVmax ratio between lymph node 
and primary tumor (LN/T SUVmax) is 
lower than 0.4, and the lymph node has 
homogeneous echogenecity during ultra-
sonographic assessment.1
In the absence of distant metas-
tasis, proper staging of mediastinum is 
of great importance for identification of 
patients who are candidates for radical 
curative therapies. Although positron 
emission tomography/computed tomog-
raphy (PET/CT) can never replace 
pathological staging, it is regarded as 
the most accurate imaging modality 
for nodal  staging. However, there are 
a significant number of false positivity 
(underlying inflammatory processes, 
such as immune reaction because 
of presence of tumor, obstructive 
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We welcome the correspondence 
from Professor Koksal and Dr. Ozmen 
in regard to our manuscript published 
in the Journal of Thoracic Oncology. 
In particular, we welcome the oppor-
tunity to correspond with some of the 
first authors to investigate the potential 
value of the “standardized uptake value 
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pneumonia, anthracosis, or granuloma-
tous inflammation) and false negativity 
(microscopic metastasis beyond spatial 
resolution of PET/CT).
In the literature, there are differ-
ent declared PET positivity criteria for a 
lymph node, but are not well validated.3 
A SUVmax level higher than the medi-
astinal blood pool is associated with 
increased probability of malignancy and 
higher sensitivity, but lower specificity.1,4 
Using a cutoff level as “SUVmax higher 
than 2.5” is sometimes low for predicting 
malignancy because of common inflam-
matory conditions. In the study by Evison 
et al., using a SUVmax value higher than 
4 to indicate PET positivity leads to a 
diagnostic performance as follows: sen-
sitivity, 89.9%; specificity, 89.6%; nega-
tive predictive value, 85.8%; positive 
predictive value 92.6%, and diagnostic 
accuracy 89.8%.1
A LN/T SUVmax ratio was first 
defined by Cerfolio et al. as a univer-
sal predictor of lymph node metastasis 
to eliminate the variation of SUVmax 
among different PET scanners. They 
documented that a ratio of 0.56 or higher 
predicts the node to be malignant with a 
chance of 94%.5 After that study, we pro-
posed a level of 0.2, which is lower than 
the study by Cerfolio et al. This low ratio 
was probably because of our study popu-
lation who were early stage cases directly 
referred to surgical resection. None of 
them have a lymph node larger than 1 cm 
in short axis diameter on CT. Besides, 
we considered a lymph node as positive 
if there was a fluoro-deoxy-D-glucose 
(FDG) uptake higher than the surround-
ing mediastinal tissue. Therefore the 
number of pathologically positive lymph 
nodes was extremely low (%14).4
Evison et al. is the first who sug-
gested a LN/T SUV max ratio of 0.4 
and validated it. We think that using 
such a LN/T SUVmax ratio instead of a 
SUVmax threshold can be important for 
tumors with low FDG activities. A tumor 
with a low FDG activity (for example 
low-grade adenocarcinomas) might have 
a metastatic lymph node with low FDG 
activity. We wonder if Evison et al. real-
ized such cases in their study group espe-
cially in EBUS-TBNA positive cases.
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To the Editor:
MET abnormalities, including 
overexpression, amplification, and 
mutation, have been described in non-
small-cell lung cancer (NSCLC). Ou 
et al.1 reported in Journal of Thoracic 
Oncology in 2011 a patient with de 
novo MET amplification and a rapid 
and durable response to the oral ALK 
and MET inhibitor, crizotinib. The util-
ity of MET amplification as a predic-
tive marker was recently confirmed in 
a larger case series, but there have been 
no data regarding the clinical signifi-
cance of MET mutations in NSCLC.
We treated a 76-year-old female 
diagnosed with metastatic squamous 
cell carcinoma of the lung in April 
2014. She was a former light smoker 
and quit tobacco use more than 30 years 
ago. Extended mutation analysis was 
performed, revealing a MET D1010H 
mutation and MDM2 amplification 
(Foundation Medicine, Cambridge, 
MA). She was initially treated with a 
combination of a novel MMP9 inhibi-
tor, carboplatin, and paclitaxel and had 
progressive disease after three cycles. 
Treatment was then changed to gem-
citabine, but after one cycle symptom-
atic disease progression occurred in 
the lung and bone and at a painful right 
It is uncommon for low-grade adeno-
carcinomas to present in such a way and 
are therefore under-represented in this 
study. This is reflected in the number 
of patients with an indeterminate pri-
mary tumor SUVmax; only 15 of 509 
patients had a primary tumor SUVmax 
less than 4.0, and just four patients had 
an SUVmax less than 2.5. From these 
15 patients, 11 patients had both inde-
terminate FDG avidity in the primary 
tumor and indeterminate avidity in the 
lymph nodes sampled by EBUS-TBNA. 
Ten of these tumors were adenocarcino-
mas plus one non-small-cell lung can-
cer not otherwise specified. The SUV 
ratio in all of the sampled lymph nodes 
was greater than 40% and ranged from 
45% to 175%. In three cases, EBUS-
TBNA confirmed N2/3 metastases. In 
the remaining eight cases, in which the 
EBUS-TBNA was negative, there were 
two false-negatives where nodal metas-
tases were subsequently diagnosed and 
six true-negatives. The risk stratification 
model indicated seven out of the eight 
cases of negative EBUS were high risk 
for false-negative sampling, suggesting 
the need for further pathological sam-
pling and two of seven were ultimately 
proven to be false-negative.
In summary, the SUV ratio does 
seem to be a useful indicator of the risk of 
nodal metastases in indeterminate FDG 
avidity tumors with indeterminate SUV 
FDG avidity in mediastinal lymph nodes. 
The risk stratification model, we presented 
in our study, therefore encompasses this 
clinical scenario and remains relevant 
to this patient group. We acknowledge 
the small number of such patients in our 
study and as such, our comments need be 
interpreted with this in mind. We would 
also stress the importance of using this 
risk stratification model for lymph nodes 
sampled with EBUS and deemed nega-
tive. It cannot replace pathological staging 
and has only been derived and validated 
in this setting.
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(SUV) ratio”; the ratio of maximum 
SUV between the primary tumor and 
mediastinal lymph nodes, on positron 
emission computed tomography (CT), 
in lung cancer patients. It was the previ-
ous work of Koksal et al. and Cerfolio 
et al. that sparked our own interest in 
the SUV ratio as a potential predictor 
of false-negative nodal sampling with 
endobronchial ultrasound-guided trans-
bronchial needle aspiration (EBUS-
TBNA). In our study, the SUV ratio 
proved to be a powerful predictor of 
nodal malignancy and false-negative 
EBUS-TBNA and is a key element of 
our risk stratification model.
Professor Koksal specifically asks 
about our experience with indeterminate 
18-F-fluorodeoxyglucose (FDG) avid-
ity tumors, for example, lepidic-type 
adenocarcinomas, and the usefulness 
of the SUV ratio in such circumstances. 
We use the term “indeterminate” to 
describe an SUVmax above that of the 
background mediastinal blood pool but 
lacking the significant FDG avidity nor-
mally associated with malignancy. Our 
first comment is that, in our experience, 
it is rare to undertake EBUS mediasti-
nal staging in such circumstances. Low-
grade adenocarcinomas are usually 
peripheral ground-glass opacities on CT 
imaging with no or indeterminate FDG 
uptake and normal hilar and mediastinal 
nodes radiologically. These tumors are 
often biologically indolent tumors, and 
therefore, nodal spread is less common. 
As per the American College of Chest 
Physicians Staging Guidelines,1 periph-
eral tumors with low or indeterminate 
FDG avidity and normal hilar/mediasti-
nal nodes radiologically do not require 
pathological nodal staging and can 
proceed directly to resection, assuming 
adequate fitness because the prevalence 
of nodal metastases is low. The preva-
lence of nodal metastases in our study 
was much higher as it predominantly 
included patients with N2/3 nodal dis-
ease on CT (376 of 509 patients, 74%). 
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